[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611982":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":34,"centralContacts":39,"locations":40,"responsibleParty":52,"collaborators":39,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":39,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":39,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":80,"whyStopped":39,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Bahria University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group B received Empagliflozin with Linagliptin","ACTIVE_COMPARATOR","Empagliflozin 10 mg, along with Tab Linagliptin 5mg.",[13],"Drug: (Empagliflozin 10 mg+ Tab Linagliptin 5mg)",{"label":15,"type":10,"description":16,"interventionNames":17},"Group A received Empagliflozin with Metformin","Tab Empagliflozin 10 mg once daily, along with combination of Tab Metformin 500 mg",[18],"Drug: Tab Empagliflozin 10 mg + Tab Metformin 500 mg",[20,29],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","(Empagliflozin 10 mg+ Tab Linagliptin 5mg)","(Empagliflozin 10 mg+ Tab Linagliptin 5mg)was given once Orally daily",[9],[26,27,28],"Diampa LT (10\u002F5 ) MG","Xenglu- Lin (10 \u002F 5 ) MG","Empaa L ( 10 \u002F 5 ) MG",{"type":21,"name":30,"description":16,"armGroupLabels":31,"otherNames":32},"Tab Empagliflozin 10 mg + Tab Metformin 500 mg",[15],[33],"Xenglu - Met XR ( 10 \u002F 500 ) MG",[35],{"name":36,"affiliation":37,"role":38},"NABILA RAFI","DOCTOR","PRINCIPAL_INVESTIGATOR",null,[41],{"facility":5,"status":39,"city":42,"state":43,"zip":39,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":39},"Karachi","Sindh","Pakistan","PK",{"type":47,"coordinates":48},"Point",[49,50],67.0104,24.8608,{"lat":50,"lon":49},{"type":38,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"Dr. Nabila Rafi","MBBS , M.PHIL PHARMACOLOGY","100611982","phase-4-the-efficacy-and-safety-of-empagliflozin---linagliptin-and-empagliflozin--metformin-therapy-in-reduction-of-body-weight-in-type-2-diabetic-patients--100611982",false,"NCT07247656","The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients .","Comparison of Empagliflozin- Linagliptin With Empagliflozin- Metformin Combination Therapy in Reduction of Body Weight in Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* • Diabetic men and women of age 40-70 yrs.\n\n  * HBA1C -(6.5-9 )percent\n  * All diabetic patients were BMI ≥25kg\u002Fm2\n  * Patient took metformin ≥1000mg\u002Fday for ≥ 3 months with uncontrolled DM\n\nExclusion Criteria:\n\n* Male and female type 1 diabetic patients with BMI \\\u003C25\n\n  * Diabetic patient taking oral medicine other than metformin for last 12 weeks\n  * Subjects with creatinine \\>1.5mg\u002Fdl\n  * Pregnant or Lactating Women\n  * Co-morbidities -\n  * CLD\n  * Cancer patient","ALL","40 Years","70 Years",{"count":66,"type":67},200,"ACTUAL","INTERVENTIONAL",[70],"PHASE4","The goal of this clinical trial is - Comparison of Empagliflozin - Linagliptin with Empagliflozin - Metformin combination therapy in reduction of body weight in T2DM Patients and it included 200 diabetic subjects with total study period of 12 weeks and individual study period of 4 weeks .",[73],"Diabete Mellitus",[75,76,77,78,79],"liver profile","BMI","Waist to Hip Ratio","Renal Function tests","HBA1C","COMPLETED","2025-11-22",{"date":83,"type":67},"2025-11-25",{"date":85,"type":67},"2022-12-01",{"date":87,"type":67},"2023-05-01",{"name":5,"class":6},1]